GSK’s Q3 Sales Boosted by Specialty Medicines Growth

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline (GSK) reported a 2% increase in core sales for Q3 2024, driven by strong performance in Specialty Medicines, which offset declines in vaccine sales due to prioritization of COVID vaccinations and guideline changes. The company also confirmed its outlook for 2024, expecting sales growth of 7-9% and core operating profit growth of 11-13%, while maintaining a dividend payout. Significant progress in R&D, including new approvals and trials in multiple therapeutic areas, further strengthens GSK’s future growth prospects.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.